Aims: To determine the minimal clinically important difference (MCID) of the Dermatology Life Quality Index (DLQI) and its responsiveness to change in inflammatory skin diseases. Methods: A longitudinal study: at stage 1, patients completed the DLQI and a disease severity global question; at stage 2, a global rating of change in quality of life (QoL; Global Rating of Change Questionnaire, GRCQ) was added and used as an anchor to measure the MCID of the DLQI. Results: 192 patients completed stage 1 and 107 completed stage 2. The mean DLQI score at stage 1 was 9.8 and 7.4 at stage 2 with a mean change of 2.4 (p < 0.0001). 31 patients experienced a ‘small change' in their QoL (±3 and ±2) on the GRCQ. The mean corresponding change in DLQI scores was 3.3, which is regarded as the approximate MCID. Conclusions: Previous estimates of the MCID of the DLQI have varied from 3 to 5. Although this study demonstrated a MCID of 3.3, we recommend that the MCID in inflammatory skin diseases should be 4.

1.
Guyatt G, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171-178.
2.
Wright JG: The minimal important difference: who's to say what is important. J Clin Epidemiol 1996;49:1221-1222.
3.
Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-87.
4.
Jaeschke R, Singer J, Guyatt GH: Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415.
5.
Crosby RD, Kolotkin RL, Williams GR: Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395-407.
6.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
7.
Basra MKA, Fenech R, Gatt RM, et al: The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:997-1035.
8.
Both H, Essink-Bot ML, Busschbach J, Nijsten T: Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007;127:2726-2739.
9.
Le Cleach L, Chassany O, Levy A, et al: Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008;216:46-55.
10.
Lewis V, Finlay AY: 10 years' experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004;9:169-180.
11.
Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P: Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol 2005;85:409-413.
12.
Bronsard V, Paul C, Prey S, et al: What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24(suppl 2):17-22.
13.
Nijsten T, Meads DM, McKenna SP: Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary. Acta Derm Venereol 2006;86:284-285.
14.
Nijsten T, Meads DM, de Korte J, et al: Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007;127:2315-2322.
15.
Twiss J, Meads DM, Preston EP, et al: Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol 2012;132:76-84.
16.
Hongbo Y, Thomas CL, Harrison MA, Salek S, Finlay AY: Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005;125:659-664.
17.
Khilji FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147 (suppl 2):50.
18.
Shikiar R, Harding G, Leahy M, Lennow RD: Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005;3:36.
19.
Shikiar R, Willian MK, Okun MM, et al: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of phase II study. Health Qual Life Outcomes 2006;4:71.
20.
Kowalski J, Ravelo A, Weng E, Slaton T: Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI) in patients with axillary and palmar hyperhidrosis. J Am Acad Dermatol 2007;56:AB52(P546).
21.
Melilli L, Shikiar R, Thompson C: Minimal clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with adalimumab. J Am Acad Dermatol 2006;54: AB221(P2894).
22.
Loo WJ, Diba VC, Chawla M, Finlay AY: Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003;148:279-284.
23.
Cohen J: Statistical Power Analysis for the Behavioural Sciences, ed 2. Hillsdale, Erlbaum Associates, 1988, pp 8-14.
24.
Norman GR, Stratford P, Regehr G: Methodological problems in the retrospective computation of responsiveness to change: The lessons of Cronbach. J Clin Epidemiol 1997;50:869-879.
25.
Stratford PW, Binkley JM, Riddle DM, Guyatt GH: Sensitivity to change of the Roland-Morris Back Pain Questionnaire: part 1. Phys Ther 1998;78:1186-1196.
26.
Hagg O, Fritzell P, Oden A, Nordwall A; the Swedish Lumbar Spine Study Group: Simplifying outcome measurement. Evaluation of instruments for measuring outcome after fusion surgery for chronic low back pain. Spine 2002;27:1213-1222.
27.
Revicki DA, Cella D, Hayes RD, Sloan JA, Lenderking WR, Aaronson NK: Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70.
28.
Smith CH, Anstey AV, Barker JNWN, et al: British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.
29.
Jayaprakasam A, Darvay A, Osborne G, McGibbon D: Comparison of assessments of severity and quality of life in cutaneous disease. Clin Exp Dermatol 2002;27:306-308.
30.
Sampogna F, Sera F, Abeni D: Measures of clinical severity, quality of life and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-607.
31.
Beaton DE, Bombardier C, Katz JN, Write JG: A taxonomy for responsiveness. J Clin Epidemiol 2001;54:1204-1217.
32.
Food and Drug Administration: Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims. Silver Spring, FDA, 2006.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.